← Back to all trials
Enrolling By Invitation
NCT07807995
A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
Conditions: Immunoglobulin A Nephropathy
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 605
Sponsor: Vertex Pharmaceuticals Incorporated
Location: Western Nephrology - Arvada Arvada Colorado
Summary
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Eligibility Criteria
Key Inclusion Criteria:
* Completed the Week 104 visit in the parent study VX24-AIS-D08 (NCT06564142) and has not permanently discontinued study drug
* Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 15 milliliters per minute (mL/min)/1.73 square meter (m\^2) within 45 days of Day 1 of this study
Key Exclusion Criteria:
\- Planned participation in another interventional, therapeutic clinical trial (other than the parent study).
Other protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT07807995). StuddyBuddy aggregates publicly available trial information.
